AKT1 and susceptibility to pneumonia measurement: Integrated network analysis combined with pharmacological assessment and in vivo validation revealed that Feilike mixture (FLKM) alleviates pneumonia by targeting core anti-inflammatory pathways (TNF/AKT1/IL6/p38MAPK) via its key bioactive components (e.g., resveratrol and stigmasterol), reducing cytokine storm and lung injury, while molecular dynamics confirmed stable ligand–receptor binding (e.g., AKT1–stigmasterol), providing mechanistic evidence for its clinical efficacy [82].